LFWD (Lifeward Ltd. Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by LFWD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Haggai Zamir | Director | A | — | — |
| 2026-08-28 | Yonason Greenwald | Director | A | — | — |
| 2026-08-24 | Avraham Gabay | Director | A | — | — |
| 2026-05-20 | Keith Dale Rose | Chief Medical Officer | A | — | — |
| 2026-04-13 | William Mark Sigsbee | Director | A | — | — |
| 2026-04-13 | Moshe H Rozenbaum | Director | A | — | — |
| 2026-03-27 | William Mark Grant | President & CEO | A | — | — |
| 2026-03-27 | Yehuda Reznick | Director | A | — | — |
| 2026-03-27 | Miriam Kidron | Director | A | — | — |
| 2026-03-27 | NADAV KIDRON | Director | A | — | — |
| 2026-03-27 | Almog Adar | Chief Financial Officer | A | — | — |
| 2025-12-12 | Jeannine Lynch | VP of Market Access & Strategy | A | — | — |
| 2025-09-04 | Jeannine Lynch | VP of Market Access & Strategy | Sell | — | — |
| 2025-08-13 | Almog Adar | Chief Financial Officer | A | — | — |
| 2025-08-07 | Hadar Levy | Director | A | — | — |
| 2025-08-07 | JOHN WILLIAM PODUSKA SR | Director | A | — | — |
| 2025-08-07 | Randel Richner | Director | A | — | — |
| 2025-08-07 | Robert J. Marshall Jr. | Director | A | — | — |
| 2025-08-07 | Joseph E Turk Jr | Director | A | — | — |
| 2025-08-07 | Michael Swinford | Director | A | — | — |
| 2025-06-04 | William Mark Grant | President & Co-CEO | A | — | — |
| 2025-05-22 | Lawrence J Jasinski | Chief Executive Officer | Sell | — | — |
| 2025-01-08 | Lind Global Fund II LP | 10%+ Owner | Sell | — | — |
| 2024-12-17 | Randel Richner | Director | Sell | — | — |
| 2024-12-17 | Joseph E Turk Jr | Director | Buy | — | — |
| 2024-11-27 | Michael Swinford | Director | Buy | — | — |
| 2024-11-26 | Michael Swinford | Director | Buy | — | — |
| 2024-11-25 | Michael Swinford | Director | Buy | — | — |
| 2024-09-16 | Lawrence J Jasinski | Chief Executive Officer | Sell | — | — |
| 2024-09-04 | Jeannine Lynch | VP of Market Access & Strategy | Sell | — | — |
| 2024-08-06 | Jeannine Lynch | VP of Market Access & Strategy | Sell | — | — |
| 2024-08-06 | Lawrence J Jasinski | Chief Executive Officer | Sell | — | — |
| 2024-07-02 | Jeannine Lynch | VP of Market Access & Strategy | Sell | — | — |
| 2024-06-21 | Lawrence J Jasinski | Chief Executive Officer | Sell | — | — |
| 2024-05-28 | Michael A Lawless | Chief Financial Officer | Buy | — | — |
| 2024-05-24 | Joseph E Turk Jr | Director | Buy | — | — |
| 2024-05-23 | Lawrence J Jasinski | Chief Executive Officer | Sell | — | — |
| 2024-04-22 | Michael Swinford | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 71,500 | — |
| — | Chief Medical Officer | 17,083 | — |
| — | Director | 13,643 | — |
| — | VP of Market Access & Strategy | 11,845 | — |
| — | Director | 11,485 | — |
| — | Director | 11,485 | — |
| — | Director | 8,748 | — |
| — | Director | 8,413 | — |
| — | Chief Executive Officer | 8,405 | — |
| — | Director | 7,657 | — |
| — | Director | 7,657 | — |
| — | Director | 7,657 | — |
| — | Director | 6,711 | — |
| — | Chief Financial Officer | 4,989 | — |
| — | Director | 4,791 | — |
| — | Director | 4,663 | — |
| — | Director | 4,298 | — |
| — | Director | 2,993 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LFWD quote page; the site-wide leaderboard is on the insider transactions hub.